ArticleFrontiers in oncology2025
Case Report: Metabolic alterations and cholesterol esterification in a low-grade diffuse astrocytoma patient who progressed to glioblastoma at recurrence.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Metabolic alterations during transformation of low-grade gliomas (LGGs) into high-grade glioblastomas (GBMs) remain incompletely understood. Particularly, IDH wildtype (IDHwt) diffuse astrocytomas harboring TERT promoter (TERTp) mutations, classified as molecular GBM under the 2021 WHO classification, may exhibit distinct metabolic and epigenetic features compared to histological WHO Grade 4 GBMs. Here, we conducted a detailed metabolomic comparison of tumor specimens from a patient initially diagnosed with WHO Grade 2 IDHwt diffuse astrocytoma carrying TERTp mutation, who subsequently progressed to a histologically confirmed WHO Grade 4 GBM upon recurrence. Case presentation: A 66-year-old female patient underwent surgical resection of a WHO Grade 2 diffuse astrocytoma in April 2018. Molecular testing revealed IDH1-wildtype status and TERTp mutation, classifying the tumor as a molecular GBM. Following ~3.5 years of clinical stability, magnetic resonance imaging detected tumor recurrence. The patient underwent a second craniotomy in February 2022, with histopathology confirming progression to WHO Grade 4 GBM. Using untargeted proton nuclear magnetic resonance ( Conclusion: Our findings identify alanine accumulation and increased cholesterol esterification as key metabolic features accompanying malignant transformation from molecular GBM to histological WHO grade-4 GBM. These metabolic changes may serve as biomarkers of tumor progression and recurrence. Importantly, alanine detection via magnetic resonance spectroscopy offers promising potential for non-invasive glioma diagnostics. Furthermore, targeting cholesterol esterification pathways using Acyl-CoA:cholesterol acyltransferase inhibitors could provide a novel therapeutic approach, especially for low-grade astrocytomas with high risk of malignant progression and recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.